Inhibition of ZEB1 by miR-200 characterizes Helicobacter pylori-positive gastric diffuse large B-cell lymphoma with a less aggressive behavior

Modern Pathology

Volumn 27, Issue 8, 2014, Pages 1116-1125

  Huang, Wei Ting ^a   Kuo, Sung Hsin ^b   Cheng, Ann Lii ^b   Lin, Chung Wu ^a  

^a NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

gastric diffuse large B cell lymphoma; miR 200; ZEB1

Indexed keywords

MESSENGER RNA; MICRORNA; MICRORNA 200; MICRORNA 200A; MICRORNA 200B; MICRORNA 200C; PROTEIN BCL 6; RITUXIMAB; TRANSCRIPTION FACTOR ZEB1; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; MICRORNA 142 3P; MICRORNA 507; MICRORNA 513; MICRORNA 520E; MICRORNA 544; MITOXANTRONE; PREDNISOLONE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; BCL6 PROTEIN, HUMAN; DNA BINDING PROTEIN; HOMEODOMAIN PROTEIN; MIRN200 MICRORNA, HUMAN; TRANSCRIPTION FACTOR; TUMOR MARKER; ZEB1 PROTEIN, HUMAN;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; EVENT FREE SURVIVAL; FEMALE; FOLLOW UP; GASTRIC DIFFUSE LARGE B CELL LYMPHOMA; GENE EXPRESSION; HELICOBACTER INFECTION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUANTITATIVE ANALYSIS; REMISSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STOMACH LYMPHOMA; SURVIVAL RATE; B LYMPHOCYTE; CANCER COMBINATION CHEMOTHERAPY; CANCER PROGNOSIS; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; DISEASE ASSOCIATION; GENETIC ASSOCIATION; GERMINAL CENTER; OVERALL SURVIVAL; TREATMENT RESPONSE; CHEMISTRY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; ISOLATION AND PURIFICATION; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICROBIOLOGY; MIDDLE AGED; MORTALITY; PATHOLOGY; PHENOTYPE; REAL TIME POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TIME; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GENOME-WIDE ASSOCIATION STUDY; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; REMISSION INDUCTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STOMACH NEOPLASMS; TIME FACTORS; TRANSCRIPTION FACTORS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84905504436     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2013.229     Document Type: Article

References (32)

1. Isaacson PG, Chott A, Nakamura S, et al. Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue (MALT lymphoma), In: Swerdlow SH, Campo E, Harris NL, et al. (eds). Tumours of Haematopoietic and Lymphoid Tissues, WHO Classification of Tumours. IARC Press: Lyon 2008, pp 214-217.
2. Ferreri AJ, Montalban C. Primary diffuse large B-cell lymphoma of the stomach. Crit Rev Oncol Hematol 2007;63 :65-71.
3. Psyrri A, Papageorgiou S, Economopoulos T. Primary extranodal lymphomas of stomach: clinical presentation, diagnostic pitfalls and management. Ann Oncol 2008;19:1992-1999.
4. Chen YW, Hu XT, Liang AC, et al. High BCL6 expression predicts better prognosis, independent of BCL6 translocation status, translocation partner, or BCL6-deregulating mutations, in gastric lymphoma. Blood 2006;108:2373-2783.
5. De Craene B, Berx G. Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 2013;13:97-110.
6. Brabletz S, Brabletz T. The ZEB/miR-200 feedback loop-a motor of cellular plasticity in development and cancer? EMBO Rep 2010;11:670-677.
7. Lamouille S, Subramanyam D, Blelloch R, et al. Regulation of epithelial-mesenchymal and mesenchymal- epithelial transitions by microRNAs. Curr Opin Cell Biol 2013;25:200-207.
8. Papadopoulou V, Postigo A, Sánchez-Tilló E, et al. ZEB1 and CtBP form a repressive complex at a distal promoter element of the BCL6 locus. Biochem J 2010; 427:541-550.
9. Arnold CN, Pirie E, Dosenovic P, et al. A forward genetic screen reveals roles for Nfkbid, Zeb1, and Ruvbl2 in humoral immunity. Proc Natl Acad Sci USA 2012;109:12286-12293.
10. Genetta T, Ruezinsky D, Kadesch T. Displacement of an E-box-binding repressor by basic helix-loop-helix proteins: implications for B-cell specificity of the immunoglobulin heavy-chain enhancer. Mol Cell Biol 1994;14:6153-6163.
11. Lemma S, Karihtala P, Haapasaari KM, et al. Biological roles and prognostic values of the epithelial-mesenchymal transition-mediating transcription factors Twist, ZEB1 and Slug in diffuse large B-cell lymphoma. Histopathology 2013;62:326-333.
12. Postigo AA, Dean DC. Independent repressor domains in ZEB regulate muscle and T-cell differentiation. Mol Cell Biol 1999;19:7961-7971.
13. Brabletz T, Jung A, Hlubek F, et al. Negative regulation of CD4 expression in T cells by the transcriptional repressor ZEB. Int Immunol 1999;11: 1701-1708.
14. Wang J, Lee S, Teh CE, et al. The transcription repressor, ZEB1, cooperates with CtBP2 and HDAC1 to suppress IL-2 gene activation in Tcells. Int Immunol 2009;21:227-235.
15. Nakahata S, Yamazaki S, Nakauchi H, et al. Downregulation of ZEB1 and overexpression of Smad7 contribute to resistance to TGF-beta1-mediated growth suppression in adult T-cell leukemia/lymphoma. Oncogene 2010;29:4157-4169.
16. Geiss GK, Bumgarner RE, Birditt B, et al. Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 2008;26: 317-325.
17. Vladislav MA. Multiplexed measurements of gene signatures in different analytes using the NanoString nCounter Assay System. BMC Research Notes 2009; 2:80.
18. Kulkarni MM. Digital multiplexed gene expression analysis using the NanoString nCounter System. Curr Protoc Mol Biol 2011; Chapter 25:Unit25B.10.
19. Sturn A, Quackenbush J, Trajanoski Z. Genesis: cluster analysis of microarray data. Bioinformatics 2002;18: 207-208.
20. Lin TC, Liu TY, Hsu SM, et al. The EBV-encoded miRBART20-5p inhibits T-bet with secondary suppression of p53 in invasive nasal NK-cell lymphoma. Am J Pathol 2013;182:1865-1875.
21. Liu TY, Chen SU, Kuo SH, et al. E2A-positive gastric MALT lymphoma has weaker plasmacytoid infiltrates and stronger expression of the memory B-cell-associated miR-223: possible correlation with stage and treatment response. Mod Pathol 2010;23:1507-1517.
22. Betel D, Koppal A, Agius P, et al. MirSVR predicted target site scoring method: comprehensive modeling of microRNA targets predicts functional non-conserved and non-canonical sites. Genome Biol 2010;11:R90.
23. Betel D, Wilson M, Gabow A, et al. MicroRNA target predictions: the microRNA.org resource: targets and expression. Nucleic Acids Res 2008;36(Database Issue):D149-D153.
24. Chung HJ, Liu J, Dundr M, et al. FBPs are calibrated molecular tools to adjust gene expression. Mol Cell Biol 2006;26:6584-6597.
25. Pinto AE, André S, Silva G, et al. BCL-6 oncoprotein in breast cancer: loss of expression in disease progression. Pathobiology 2009;76:235-242.
26. Hirata Y, Ogasawara N, Sasaki M, et al. BCL6 degradation caused by the interaction with the C-terminus of pro-HB-EGF induces cyclin D2 expression in gastric cancers. Br J Cancer 2009; 100:1320-1329.
27. Barton S, Hawkes EA, Wotherspoon A, et al. Are we ready to stratify treatment for diffuse large B-cell lymphoma using molecular hallmarks? Oncologist 2012;17:1562-1573.
28. Basso K, Dalla-Favera R. Roles of BCL6 in normal and transformed germinal center B cells. Immunol Rev 2012;247:172-183.
29. Kuo SH, Chen LT, Lin CW, et al. Detection of the Helicobacter pylori CagA protein in gastric mucosaassociated lymphoid tissue lymphoma cells: clinical and biological significance. Blood Cancer J 2013;3:e125.
30. Lin WC, Tsai HF, Kuo SH, et al. Translocation of Helicobacter pylori CagA into human B lymphocytes, the origin of mucosa-associated lymphoid tissue lymphoma. Cancer Res 2010;70:5740-5748.
31. Chung KM, Chang ST, Huang WT, et al. Bcl-6 expression and lactate dehydrogenase level predict prognosis of primary gastric diffuse large B-cell lymphoma. J Formos Med Assoc 2013;112:382-389.
32. Kuo SH, Yeh KH, Wu MS, et al. Helicobacter pylori eradication therapy is effective in the treatment of early-stage H. pylori-positive gastric diffuse large B-cell lymphomas. Blood 2012;119:4838-4844.